Medications for Obesity

医学 利拉鲁肽 减肥 奥利斯特 不利影响 肥胖 芬特明 安非他酮 恶心 食欲 2型糖尿病 内科学 内分泌学 糖尿病 戒烟 病理
作者
Kimberly A. Gudzune,Robert F. Kushner
出处
期刊:JAMA [American Medical Association]
卷期号:332 (7): 571-571 被引量:193
标识
DOI:10.1001/jama.2024.10816
摘要

Importance: Obesity affects approximately 19% of women and 14% of men worldwide and is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite and significantly improve outcomes, such as type 2 diabetes, hypertension, and dyslipidemia. Observations: AOMs should be administered in combination with lifestyle interventions and can be classified according to their mechanisms of action. Orlistat modifies digestive tract absorption and causes gastrointestinal adverse effects, such as oily fecal spotting and urgency, in more than 25% of patients. Centrally acting drugs, such as phentermine-topiramate and naltrexone-bupropion, regulate appetite in the brain and are associated with constipation in approximately 20% of patients, although the incidence of other adverse effects (eg, paresthesia, nausea) varies by medication. Nutrient-stimulated hormone-based medications, such as liraglutide, semaglutide, and tirzepatide, mimic the actions of enteropancreatic hormones that modify central appetite regulation and provide multiple cardiometabolic weight-loss benefits. Adverse effects of these drugs include nausea (28%-44%), diarrhea (21%-30%), and constipation (11%-24%). The relative potency of adult obesity medications has been studied in meta-analyses. Compared with placebo, orlistat was associated with 3.1% greater weight loss (52 randomized clinical trials [RCTs]; 16 964 participants), phentermine-topiramate was associated with 8.0% greater weight loss (5 RCTs; 3407 participants), naltrexone-bupropion was associated with 4.1% greater weight loss (6 RCTs; 9949 participants), liraglutide was associated with 4.7% greater weight loss (18 RCTs; 6321 participants), semaglutide was associated with 11.4% greater weight loss (5 RCTs; 4421 participants), and tirzepatide 15 mg was associated with 12.4% greater weight loss (6 RCTs; 1972 participants). Conclusion and Relevance: Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
曾志伟发布了新的文献求助20
3秒前
炼金术士完成签到,获得积分10
6秒前
7秒前
7秒前
英姑应助Tonald Yang采纳,获得10
8秒前
领导范儿应助舒服的寻琴采纳,获得10
8秒前
9秒前
LIJIngcan完成签到 ,获得积分10
10秒前
汤易非发布了新的文献求助10
13秒前
辛勤的囧完成签到,获得积分10
14秒前
平常澜完成签到 ,获得积分10
16秒前
子卿完成签到,获得积分10
17秒前
21秒前
橙橙完成签到 ,获得积分10
22秒前
26秒前
ironsilica发布了新的文献求助10
26秒前
123456777完成签到 ,获得积分0
28秒前
王泰一发布了新的文献求助10
29秒前
30秒前
爱上百香果完成签到,获得积分10
30秒前
32秒前
33秒前
33秒前
Frank应助科研通管家采纳,获得10
33秒前
33秒前
wxt完成签到,获得积分10
36秒前
猪哥完成签到 ,获得积分10
36秒前
回火青年发布了新的文献求助10
36秒前
赵yy完成签到,获得积分0
37秒前
37秒前
wkwwkwkwk完成签到 ,获得积分10
39秒前
小吴是RICH完成签到 ,获得积分10
41秒前
小井盖完成签到 ,获得积分10
41秒前
王泰一发布了新的文献求助10
43秒前
zsy35098完成签到,获得积分10
43秒前
曾志伟发布了新的文献求助20
47秒前
杨啸林完成签到 ,获得积分10
48秒前
49秒前
甄天赏完成签到,获得积分10
49秒前
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane Insecta, Polyneoptera 2000
Emmy Noether's Wonderful Theorem 1200
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
基于非线性光纤环形镜的全保偏锁模激光器研究-上海科技大学 800
Signals, Systems, and Signal Processing 610
Research Methods for Business: A Skill Building Approach, 9th Edition 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6410717
求助须知:如何正确求助?哪些是违规求助? 8230001
关于积分的说明 17463833
捐赠科研通 5463712
什么是DOI,文献DOI怎么找? 2886990
邀请新用户注册赠送积分活动 1863426
关于科研通互助平台的介绍 1702532